In addition, we have developed a bifunctional protein with a ligand that binds cell surface proteins on cancer cells to direct a sialidase specifically to the cancer cell surface and demonstrated efficacy in targeted HER2 in breast cancer (56, 57). Here, ERBB2 is linked to breast carcinoma.